Compugen Ltd. (TLV:CGEN)
573.50
-13.90 (-2.37%)
Oct 23, 2025, 3:22 PM IDT
Compugen Revenue
Compugen had revenue of $1.26M USD in the quarter ending June 30, 2025, a decrease of -81.24%. This brings the company's revenue in the last twelve months to $22.14M, down -48.16% year-over-year. In the year 2024, Compugen had annual revenue of $27.86M, down -16.72%.
Revenue (ttm)
$22.14M
Revenue Growth
-48.16%
P/S Ratio
7.20
Revenue / Employee
$299.24K
Employees
74
Market Cap
536.95M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.86M | -5.60M | -16.72% |
Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
Dec 31, 2020 | 2.00M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teva Pharmaceutical Industries | 56.02B |
Danel (Adir Yeoshua) | 2.84B |
Novolog (Pharm-Up 1966) | 2.04B |
Ilex Medical | 927.57M |
Kamada | 571.15M |
InterCure | 243.12M |
SofWave Medical | 234.12M |
BrainsWay | 155.27M |
Compugen News
- 10 days ago - Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 - PRNewsWire
- 17 days ago - Compugen to Present at SITC 2025 - PRNewsWire
- 6 weeks ago - Compugen to Present Research at the Single Cell Genomics 2025 Conference - PRNewsWire
- 2 months ago - Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 2 months ago - Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients - Seeking Alpha
- 2 months ago - Compugen signals leadership transition and advances COM701 ovarian cancer trial with interim data targeted for 2026 - Seeking Alpha
- 2 months ago - Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Compugen misses Q2 estimates - Seeking Alpha